logo
How to get a job at the FDA? Here's everything young professionals should know

How to get a job at the FDA? Here's everything young professionals should know

Time of India3 days ago
The US Food and Drug Administration (FDA) is one of the most influential public health agencies in the world. From regulating the food we eat and the medicines we take, to overseeing cutting-edge medical devices and vaccines, the FDA plays a vital role in shaping the nation's health landscape.
Tired of too many ads? go ad free now
For students and young professionals who want to make a meaningful impact on public health, a career at the FDA offers both purpose and prestige.
But how exactly does one get started?
What the FDA actually does
While many think of the FDA purely as a science agency, its responsibilities stretch far beyond the lab. The agency hires professionals from a wide range of backgrounds—scientists, doctors, engineers, data analysts, public health experts, lawyers, policy makers, and even communicators and IT specialists.
For instance, if you're majoring in biology or chemistry, you might fit into roles dealing with food safety or pharmaceutical review. If you're a public health student, epidemiology and regulatory policy might interest you. Law and political science graduates can pursue careers in compliance or policy analysis, while engineers may work on assessing medical device safety. In short, there's no single path in—there are many.
Building the right educational foundation
Most positions at the FDA require at least a bachelor's degree, and more technical or research-heavy roles often prefer a master's, PhD, PharmD, JD, or MD. Students hoping to enter scientific or regulatory careers should pursue degrees in fields like biology, microbiology, pharmacology, toxicology, biochemistry, or biomedical engineering. Those interested in policy, law, or communication can major in public health, public administration, political science, or law.
Tired of too many ads? go ad free now
Academic excellence is important, but what also stands out is coursework or experience in areas like data analysis, clinical trials, research methods, bioethics, or FDA regulatory systems. Taking relevant electives or doing a thesis related to health regulation or safety can strengthen your application.
Internships and fellowships: The smartest entry points
If you're still in school, or recently graduated, your best bet is to gain entry through an internship or fellowship.
The FDA offers multiple programs designed specifically for early-career professionals.
One of the most accessible is the Pathways Program, which includes internships for current students and special hiring opportunities for recent graduates. These positions are paid and often lead to full-time roles within the agency.
For those with advanced degrees, the FDA Commissioner's Fellowship Program is highly prestigious.
This two-year, full-time program gives fellows the chance to work on real-world regulatory issues and collaborate with leading FDA scientists and policy makers.
There's also the ORISE Fellowship Program, which partners with the FDA to offer short- and long-term research positions. These fellowships are ideal for students in STEM fields who want to gain hands-on experience in public health and regulatory science.
Each summer, the FDA also hosts students for short-term research internships in labs and policy offices. These summer opportunities are competitive, but they offer valuable exposure to the agency's mission and operations.
Navigating the federal hiring system
All permanent jobs and many internships at the FDA are posted on USAJobs.gov, the official job portal for the USgovernment. Applying through this site can feel intimidating at first, but it's manageable once you understand the format.
First, you'll need to create a USAJobs account and upload a federal-style resume—which is usually much longer and more detailed than private-sector resumes. These resumes should include your full education history, detailed descriptions of work and volunteer experience, skills, certifications, and any honors or awards.
Job announcements on the site are detailed and may include questionnaires, writing samples, or transcripts.
Be sure to read each posting thoroughly, tailor your application to the specific role, and submit all required documents before the deadline.
The citizenship question and international applicants
It's important to note that most FDA jobs require US citizenship, especially for permanent roles. However, students or researchers who are not citizens may still be eligible for certain internships or fellowships, especially those run through academic institutions or programs like ORISE.
International students interested in working with the FDA should consider partnerships through US universities or look for collaborative opportunities with other international health organizations.
The bottom line
Joining the FDA is not just about credentials—it's about passion for public service, dedication to science and health, and a willingness to learn. Start early by exploring internship opportunities, talking to mentors in your field, and following the agency's work in current affairs.
Working at the FDA means having a front-row seat to decisions that affect millions. For students and young professionals, it's a place where your knowledge can meet real-world impact.
TOI Education is on WhatsApp now. Follow us
.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

The Wire

time36 minutes ago

  • The Wire

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

Tampa (Florida) [USA], August 4: Concept Medical Inc., a global pioneer in drug-delivery technologies, today announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first enrollment marks a major milestone in the company's mission to revolutionize coronary artery disease (CAD) treatment and expands Concept Medical's clinical program into the United States and Europe. The first patient was enrolled at Mount Sinai Hospital in New York by Dr. Samin Sharma, Director of Interventional Cardiology [KG1], marking a crucial step in advancing treatment options for patients with small-vessel coronary artery disease. 'Today marks a great feat for us and for the MAGICAL-SV trial,' said Dr. Samin Sharma. 'My team at Mount Sinai is privileged to be the first to begin this study. This is a proud moment for all of us, especially knowing what the trial signifies and aims to achieve by evaluating MagicTouchas a potential alternative for treating small vessels in the U.S.' This initial U.S. enrollment follows the FDA's IDE approval of Concept Medical's MagicTouch SCB and boosts the company's broader coronary clinical program. Concept Medical is now actively enrolling in three IDE trials concurrently in the U.S., spanning across coronary and peripheral interventions and underscoring its commitment to bringing innovative therapies to patients worldwide. MAGICAL-SV is a prospective, multicenter, single-blind randomized trial (2:1 randomization) comparing Concept Medical's MagicTouch sirolimus-coated balloon to drug-eluting stents (Everolimus eluting stents [EES] or Zotarolimus eluting stents [ZES]) for the treatment of small coronary artery lesions. Randomization is stratified by study site and presence of medically-treated diabetes mellitus status. The trial will enroll 1,605 patients across the U.S. and Europe, to evaluate the primary endpoint of target lesion failure (TLF) at 12 months. The MAGICAL-SV trial is led by an international team of renowned cardiologists, Dr. Martin B. Leon (USA) serves as Study Chair, with principal investigators (PI) Dr. Azeem Latib (USA), Dr. Ajay Kirtane (USA), and Prof. Antonio Colombo (Europe). Dr. Azeem Latib, a U.S. PI for MAGICAL-SV, noted, 'The first U.S. patient enrollment in the MAGICAL-SV study marks an exciting step forward in building robust evidence for sirolimus-coated balloon technology in the treatment of small-vessel coronary disease. As we explore metal-free PCI strategies, this study brings renewed hope for safer, more effective options for our patients.' Prof. Antonio Colombo, who leads the European arm of the study, added, 'Starting small and going big! MAGICAL-SV represents an important step in building evidence for sirolimus-coated balloons.' This milestone embodies a 'leave nothing behind' philosophy in coronary interventions, treating arterial blockages without permanent implants and addressing the limitations of metallic stents in small vessels. Dr. Martin B. Leon, the Study Chair, emphasized the significance of evaluating a no-stent strategy through this trial: 'The initiation of the MAGICAL-SV trial marks an important step in evaluating sirolimus-coated balloon therapy for small coronary vessels. By addressing key limitations of stenting in this complex anatomy, the study aims to generate strong comparative data versus DES. The results could inform future treatment strategies in the U.S. and Europe, offering clinicians a potential alternative for managing small-vessel disease.' With this pioneering trial, MAGICAL-SV is expected to yield compelling clinical evidence in support of sirolimus-coated balloon therapy. The outcomes will also support Concept Medical's Pre-Market Approval (PMA) application for the MagicTouch SCB in small-vessel indication, potentially transforming the standard of care in coronary artery disease. Dr. Manish Doshi, Founder and Managing Director of Concept Medical, said, 'At Concept Medical, our unwavering commitment to innovation and patient care drives us to push the boundaries of what is possible in vascular interventions. The initiation of MAGICAL-SV reinforces our dedication to delivering next-generation, evidence-based solutions to clinicians and patients across the globe. Our ultimate goal is to transform the current standard of care and provide better outcomes and quality of life for patients affected by CAD.' About MagicTouch SCB MagicTouch SCB is Concept Medical's sirolimus-coated balloon platform, developed with proprietary Nanoluté technology to deliver sub-micron particles of sirolimus in a biocompatible carrier for deep arterial wall penetration. The device has received CE Mark approval in Europe and a Breakthrough Device designation from the U.S. FDA for small coronary vessels and in-stent restenosis. About Concept Medical Concept Medical Inc., headquartered in Tampa, Florida, is a global leader in cutting-edge drug-delivery technologies for cardiovascular interventions. The company is dedicated to improving patient care through research and development of novel drug-delivery platforms engineered to precisely deliver therapeutic agents to diseased vascular tissue. Concept Medical's MagicTouch family of sirolimus-coated balloons is the world's first and most widely used SCB technology, recognized for its versatility, safety and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have treated over one million patients worldwide, setting a new benchmark in vascular therapy. For media inquiries, please contact: pr@ (Disclaimer: The above press release comes to you under an arrangement with PNN and PTI takes no editorial responsibility for the same.). PTI This is an auto-published feed from PTI with no editorial input from The Wire.

'Irreplaceable For Americans': Pharmexcil Chief Says India's Low-Cost Drug Edge Can't Be Matched Overnight
'Irreplaceable For Americans': Pharmexcil Chief Says India's Low-Cost Drug Edge Can't Be Matched Overnight

News18

time5 hours ago

  • News18

'Irreplaceable For Americans': Pharmexcil Chief Says India's Low-Cost Drug Edge Can't Be Matched Overnight

Last Updated: The US remains dependent on India for affordable medicines – and that is unlikely to change anytime soon India has become too central to global drug supply to be marginalised – not even by the United States – so much so that it has made itself 'irreplaceable". The chief of India's pharmaceuticals export body, Namit Joshi told News18 that India exports 55 percent to the United States and United Kingdom – the most stringent markets in the world. 'We export 55% to the US and UK – the most stringent markets in the world. Imagine the level of compliance the Indian industry has achieved," said Joshi, who is the chairman of Pharmaceuticals Export Promotion Council of India (Pharmexcil), a body under the Ministry of Commerce and Industry. For Joshi, the latest tariff talk is more about politics than policy. 'There is a big difference between announcement and reality," he said. 'On diplomatic levels, such announcements, I believe, are made to enter into bilateral negotiations." He cited US President Donald Trump's repeated threats – to India, China, Canada, and Mexico. 'All those deals are still open. Talks are ongoing. Nothing conclusive yet… hence, there is no need to panic only about the announcements." Joshi is clear: the US cannot replicate India's drug ecosystem anytime soon. 'As much as Trump wants to MAGA (Make America Great Again), the US can't replace India," he said. 'Fixed costs in the US are too high, 42% of the population is obese, average chronic disease-free life is just 63 years – there's huge demand for medicines. But they don't have the talent or cost base to make them locally," he said. He added: 'For now, and for the foreseeable future, the world still needs Indian drugs. And India is ready to deliver." GLOBAL DEMAND, LOCAL FRAGILITY The US remains dependent on India for affordable medicines – and that's unlikely to change anytime soon. 'The US won't be able to develop our capabilities to manufacture low-cost drugs overnight," Joshi said. 'It will take at least two to three years to develop a local industry – and I'm not sure they'll find the right skill and talent even then," he said. India's cost advantage isn't the only barrier. 'We spend 12% of industry earnings just to maintain US FDA-approved facilities," he says. 'Countries like Pakistan, Bangladesh, China, Sri Lanka – they have all tried to compete. But they haven't matched us on quality or pricing, he added." China, despite its strength in chemicals and backward integration, still lags in formulations. 'It is a leader in producing KSMs and intermediaries, supplying to the globe, yet it is still not able to match India's capabilities and pricing." THE WORLD IS WATCHING – AND ALSO LEARNING Many governments may be pursuing localisation, but their strategies look very different from India's. 'Localising drug manufacturing is not everyone's play," Joshi said. 'The Netherlands is coming to iPHEX this year; they're developing a local pharma, but focused on high-end, expensive products. That won't hurt us. If anything, they're learning from us," he said. Pharmexcil is set to host its annual international expo, iPHEX, at Bharat Mandapam in New Delhi from September 4 to 6. For the first time, it is being organised without any financial support from the Centre. 'The event will host 350 international delegates from over 100 countries, including regulators, buyers, and policymakers. Exhibitors will showcase Indian strengths in APIs, formulations, diagnostics, digital health, biosimilars, and more," Joshi said. India's pharmaceutical exports have grown at a compound annual rate of 11 percent over the past decade, with a 9.54 percent increase last year alone. But Joshi knows generics alone won't fuel the future. 'The next growth lever will be achieved via innovation," he said. 'Biologics, CAR-T therapies, oncology, transplant medicines, super-speciality areas – this is where the next frontier lies." He cites Wockhardt's Zaynich as a made-in-India innovation that marks a turning point. 'We can plan our generic pipeline around upcoming patent expiries like Semaglutide, but original innovation is what will add real value." Get breaking news, in-depth analysis, and expert perspectives on everything from politics to crime and society. Stay informed with the latest India news only on News18. Download the News18 App to stay updated! tags : Pharmaceuticals view comments Location : New Delhi, India, India First Published: August 04, 2025, 09:00 IST News india 'Irreplaceable For Americans': Pharmexcil Chief Says India's Low-Cost Drug Edge Can't Be Matched Overnight Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

Over 29,000 Kg Of Butter Recalled In US For This Serious Reason
Over 29,000 Kg Of Butter Recalled In US For This Serious Reason

NDTV

time12 hours ago

  • NDTV

Over 29,000 Kg Of Butter Recalled In US For This Serious Reason

More than 29,000 kilos (64,800 pounds) of butter have been voluntarily recalled after it was discovered the packaging forgot to mention a crucial detail - it contains milk. Milk in butter might sound obvious, right? But when it is not listed on the label and someone with a milk allergy unknowingly consumes it, things can get serious real quick. On July 30, the US Food and Drug Administration (FDA) classified the recall as a 'Class II' level. That is one notch below the most urgent level. According to the FDA website, a Class II recall refers to "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." Here, a 'recall' is a safety step to remove or correct a product that is not meeting regulatory standards or could harm consumers. The butter being recalled is from Bunge North America Inc., a food company based in Missouri. On July 14, they voluntarily recalled 1,800 cases of their NH European Style Butter Blend (500 gm packs). Each case had 36 blocks of butter, packed in white paperboard boxes. The problem? Milk, a major food allergen, wasn't mentioned anywhere on the product label. The company said the recalled butter was sent to 12 distribution centres across the US and one in the Dominican Republic. So far, there is no official word from the FDA on whether anyone has fallen ill from eating the product. Allergen labelling rules are in place for a reason. As the FDA explains, food-related allergic reactions can range from mild (like hives, vomiting, diarrhoea or lip swelling) to severe, life-threatening ones like anaphylaxis. That is when the immune system goes into overdrive and releases a flood of chemicals, sending the body into shock. This is potentially fatal if not treated quickly. Because of such risks, the FDA enforces strict regulations to make sure allergens are clearly declared on packaging. The FDA advises that if someone with a milk allergy has already eaten the butter and is experiencing symptoms, "stop eating the food immediately, evaluate the need to use emergency medication (such as epinephrine) and seek medical attention." Butter is made from cream, not straight from plain milk. The cream is separated, pasteurised, then churned until fat separates and forms butter. That clumpy fat is processed, washed, worked, sometimes salted, and packaged into the block you buy. Earlier this week, High Noon Hard Seltzers were recalled after a labelling mix-up led to some vodka-filled cans being mistakenly packaged as non-alcoholic Celsius Astro Vibe Energy Drink. Read all about it here.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store